Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer, J Pathol, vol.231, pp.63-76, 2013. ,
Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions, Nat Med, vol.19, pp.614-622, 2013. ,
Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value, PLoS Med, vol.10, 2013. ,
Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition, Int J Cancer, vol.134, pp.552-62, 2014. ,
A colorectal cancer classification system that associates cellular phenotype and responses to therapy, Nat Med, vol.19, pp.619-644, 2013. ,
Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines, BMC Med Genomics, vol.5, p.66, 2012. ,
The consensus molecular subtypes of colorectal cancer, Nat Med, vol.21, pp.1350-1356, 2015. ,
PrPC from stem cells to cancer, Front Cell Dev Biol, vol.2, p.55, 2014. ,
Prions: protein aggregation and infectious diseases, Physiol Rev, vol.89, pp.1105-52, 2009. ,
Functions of the prion protein, Prog Mol Biol Transl Sci, vol.150, pp.1-34, 2017. ,
Regulation of embryonic cell adhesion by the prion protein, PLoS Biol, vol.7, p.55, 2009. ,
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proc Natl Acad Sci U S A, vol.102, pp.15545-50, 2005. ,
, Comprehensive molecular characterization of human colon and rectal cancer, Nature, vol.487, pp.330-337, 2012.
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets, Nat Commun, vol.6, p.7002, 2015. ,
FOLFIRI +bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9-FFCD 0802). Dig Liver Dis Off, J Ital Soc Gastroenterol Ital Assoc Study Liver, vol.47, pp.271-273, 2015. ,
Bevacizumab maintenance versus no maintenance during chemotherapy-free intervals in metastatic colorectal cancer: a randomized phase III trial (PRODIGE 9, J Clin Oncol Off J Am Soc Clin Oncol, vol.36, pp.674-81, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01728824
Application of a time-resolved fluoroimmunoassay for the analysis of normal prion protein in human blood and its components, Vox Sang, vol.77, pp.88-96, 1999. ,
Stromal gene expression defines poor-prognosis subtypes in colorectal cancer, Nat Genet, vol.47, pp.320-329, 2015. ,
Colorectal cancer consensus molecular subtypes translated to preclinical models uncover potentially targetable cancer cell dependencies, Clin Cancer Res Off J Am Assoc Cancer Res, vol.24, pp.794-806, 2018. ,
Genomic determinants of protein abundance variation in colorectal cancer cells, Cell Rep, vol.20, pp.2201-2215, 2017. ,
5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency, Br J Cancer, vol.103, pp.340-346, 2010. ,
The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease, Dev Camb Engl, vol.141, pp.1614-1640, 2014. ,
The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation, Genes Dev, vol.24, pp.1106-1124, 2010. ,
Genomewide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth, Nat Cell Biol, vol.17, pp.1218-1245, 2015. ,
Yap-dependent reprogramming of Lgr5(+) stem cells drives intestinal regeneration and cancer, Nature, vol.526, pp.715-723, 2015. ,
Prognostic factors in patients with non resectable metastatic colorectal cancer in the era of targeted biotherapies: relevance of Köhne's risk classification. Dig Liver Dis Off, J Ital Soc Gastroenterol Ital Assoc Study Liver, vol.45, pp.330-335, 2013. ,
Prion protein: from physiology to cancer biology, Cancer Lett, vol.290, pp.1-23, 2010. ,
CD44/cellular prion protein interact in multidrug resistant breast cancer cells and correlate with responses to neoadjuvant chemotherapy in breast cancer patients, Mol Carcinog, vol.53, pp.686-97, 2013. ,
Disruption of prion protein-HOP engagement impairs glioblastoma growth and cognitive decline and improves overall survival, Oncogene, vol.34, pp.3305-3319, 2014. ,
Cellular prion protein (PrPC) in the development of Merlin-deficient tumours, Oncogene, vol.36, pp.6132-6174, 2017. ,
CD44-positive cancer stem cells expressing cellular prion protein contribute to metastatic capacity in colorectal cancer, Cancer Res, vol.73, pp.2682-94, 2013. ,
Engagement of cellular prion protein with the co-chaperone Hsp70/90 organizing protein regulates the proliferation of glioblastoma stem-like cells, Stem Cell Res Ther, vol.8, p.76, 2017. ,
Prion protein binding to HOP modulates the migration and invasion of colorectal cancer cells, Clin Exp Metastasis, vol.33, pp.441-51, 2016. ,
Cellular prion protein contributes to LS 174T colon cancer cell carcinogenesis by increasing invasiveness and resistance against doxorubicininduced apoptosis, Tumour Biol J Int Soc Oncodeve Biol Med, vol.36, pp.8107-8127, 2015. ,
Cellular prion protein enhances drug resistance of colorectal cancer cells via regulation of a survival signal pathway, Biomol Ther, vol.26, pp.313-334, 2018. ,
Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer, JCI Insight, vol.5, 2019. ,
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer, Nat Rev Cancer, vol.17, p.268, 2017. ,
The Hippo pathway in intestinal regeneration and disease, Nat Rev Gastroenterol Hepatol, vol.13, pp.324-361, 2016. ,
YAP/TAZ at the roots of cancer, Cancer Cell, vol.29, pp.783-803, 2016. ,